15 January 2021 in Diagnostic and Interventional Radiology
We aimed to compare duration of uterine artery embolization, radiation exposure, safety and quality of life associated with the procedure in patients undergoing uterine artery embolization using transradial and transfemoral access. This randomized controlled trial was conducted from February 2013 to March 2017 in three hospitals. Transradial access was used in 78 patients and transfemoral access in 75 patients. Clinical characteristics of the patients were comparable between the two groups. Patients were evaluated for the success and duration of the procedure, radiation exposure, major and minor complications. Quality of life associated with the procedure was assessed among patients with uterine fibroids. Embolization procedures were successfully performed in all patients in both groups. The duration of uterine artery embolization (32.27±7.99 vs. 39.24±9.72 minutes, P < 0.001), uterine artery catheterization time (12.36±5.73 vs. 19.08±6.06 minutes, P < 0.001) and radiation exposure (0.28±0.14 vs. 0.5±0.21 mZv, P < 0.001) were significantly lower in the transradial access group. The rate of major (0% vs. 2.7%, P = 0.37) and minor (11.53% vs. 17.3%, P = 0.42) complications was comparable between the two groups. Transradial access was associated with a statistically significant improvement in the quality of life associated with the procedure among patients with uterine fibroids. Transradial access in uterine artery embolization has the same efficacy and safety compared to transfemoral access. This access reduces radiation exposure and duration of the procedure.
9 November 2022 in Russian Journal of Oncology
ХРХайрутдинов Евгений Рафаилович
Хайрутдинов Евгений Рафаилович
АВАраблинский Александр Владимирович
Араблинский Александр Владимирович
BACKGROUND: Pancreatic cancer is one of the most aggressive malignant neoplasms, and the results of treatment of which remain extremely unsatisfactory. One of the methods to increase the effectiveness of surgical treatment of pancreatic cancer is selective oil chemoembolization of the pancreatic arteries. Transfemoral access is typically used as a vascular access during this type of intervention, in which complications from the vascular access are often observed. AIM: This study aimed to analyze the results of the use of transradial and transfemoral approaches for chemoembolization of pancreatic cancer. MATERIALS AND METHODS: We analyzed the results of chemoembolization of pancreatic arteries in 32 patients with pancreatic cancer. Transfemoral access was used in 16 (50%) patients and transradial access in 16 (50%) patients. According to the main clinical and anamnestic data, both groups were comparable. The endpoints of the study were technical success and complication rate of chemoembolization, total duration of the procedure, time needed for catheterization of the target artery, radiation exposure, and degree of discomfort for the patient. RESULTS: Chemoembolization of pancreatic arteries was successfully performed in 100% of patients in both groups. Major vascular complications were observed in three (18.8%) patients in the transfemoral access group and in one (6.3%) in the transradial access group (p=0.6). The total duration of the procedure and the time needed for catheterization of the target artery were 54.546.61 and 51.306.46 min (p=0.17) and 12.7 and 13.25 min (p=0.72), respectively. Radiation exposure was 0.680.10 mSv in the transfemoral access group and 0.650.10 mSv in the transradial access group (р=0.4). Transradial access was associated with a statistically significant reduction in all parameters of procedural discomfort. CONCLUSION: In terms of efficiency and safety of use, the transradial approach is not inferior to the traditional transfemoral approach, and in terms of patient comfort, it can be recommended as a priority for chemoembolization of the pancreatic arteries.
27 October 2023 in Ural Medical Journal
Introduction Malignant neoplasms of the liver are one of the most common pathologies in oncology. Chemoembolization of the hepatic artery is currently widely used in the treatment of unresectable liver tumors. Transradial vascular access is actively used in interventional cardiology due to fewer local vascular complications. At the same time, until recently, chemoembolization of the hepatic artery was more often performed via transfemoral vascular access.The aim of the work is a comparative analysis of the results of transradial and transfemoral vascular accesses for the purpose of hepatic artery chemoembolization.Material and methods The data of 69 patients who underwent 212 hepatic artery chemoembolization procedures for malignant neoplasms in the liver were analyzed. The group of transradial access included 107 (50.5 %) interventions, the group of transfemoral access – 105 (49.5 %). The groups were comparable in terms of the main initial clinical and anamnestic data.Results Chemoembolization of the hepatic artery was successfully performed in 98.1 % in the transradial access group and 99 % in the transfemoral access group (p = 1.0). The total duration of intervention, time spent on catheterization of the target artery and radiation exposure were significantly shorter in the transradial access group than in the opposite group. The incidence of local vascular complications was not significantly different between the groups: 11 (10.3 %) and 12 (11.4 %) cases, respectively (p = 0.79). According to the results of patient interviews, the use of transradial access was accompanied by significantly less discomfort associated with the procedure.Discussion Traditionally, embolization of peripheral arteries is performed via transfemoral access, and the total incidence of local vascular complications (large subcutaneous hematomas, false aneurysms, arterovenous fistulas, etc.) is relatively high. According to the results of studies, it is possible to reduce the incidence of local vascular complications without increasing the cost of the procedure by performing the same interventions using transradial access.Conclusion Transradial vascular access has a number of significant advantages over transfemoral access, and therefore can be recommended as a priority for performing hepatic artery chemoembolization.
14 January 2026 in Rational Pharmacotherapy in Cardiology
Aim . To determine plasma concentrations of direct oral anticoagulants (DOACs) in patients with ischemic stroke (IS) associated with atrial fibrillation (AF) and to compare them with DOAC levels in patients with AF but without IS receiving similar therapy. Material and methods. A prospective cohort study was conducted at the Vascular Center of S.P. Botkin Moscow City Clinical Hospital from April 2022 to April 2023. The study included 82 patients with cardioembolic stroke on the background of AF (main group) and 130 AF patients without stroke or transient ischemic attack (TIA) (control group). All patients had been receiving DOACs (apixaban or rivaroxaban) for at least 3 months. Diagnostic workup included brain computed tomography, сarotid ultrasound, laboratory tests, and stroke severity assessment by NIH Stroke Scale (NIHSS). Plasma DOAC concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The lower limit of quantification (LLOQ) was 5 ng/mL. Results . Patients in the main group had significantly more frequent subtherapeutic DOAC concentrations below the LLOQ compared to the control group (52.4% vs. 1.5%, p<0.001). Subgroup analysis revealed that 58.5% of patients on rivaroxaban and 41.4% of patients on apixaban had concentrations below LLOQ, compared to 2.5% and 0% in the control group, respectively (p<0.001 for both). Inappropriately reduced DOAC doses were observed in 45.1% of the primary group versus 19.2% of controls (p<0.001). Stroke severity assessed by NIHSS and mortality did not differ significantly between patients with DOAC concentrations below LLOQ and those with therapeutic levels. Patients with stroke had a higher CHA2DS2-VASc risk score, with a median of 6 points (p<0.001). Conclusion . A significant proportion of patients with AF and cardioembolic ischemic stroke exhibit plasma concentrations of DOACs below LLOQ, which may contribute to stroke occurrence despite prescribed therapy. These findings emphasize the need to develop clinical criteria for selecting patients who require DOAC concentration monitoring and personalized therapy to reduce the risk of thrombotic events.